Urenco ChemPlants owns and will operate our most recent nuclear new build, Urenco’s Tails Management Facility.
Urenco ChemPlants Read moreSee what actions we are taking to achieve net zero by 2040 in our net zero transition plan.
Read it hereOur increased order book and solid financial and operational performance provide basis for future growth.
Read our latest report25 July 2011
The Urenco Board reaffirmed its commitment to the building of a Tails Management Facility at the Group’s UK site based at Capenhurst near Chester.
Urenco readily acknowledges its responsibility for the safe stewardship of uranium. In this respect, a comprehensive review of the project resulted in approval being given to move from the design phase to full execution, with the commencement of construction in early 2012. It is anticipated that the facility will become fully operational towards the end of 2015.
On completion, the Tails Management Facility will process Urenco’s European inventory of depleted uranium by-product reflecting the Group’s commitment to reducing its impact on the environment.
About Urenco
Urenco is an international supplier of enrichment services and fuel cycle products with sustainability at the core of its business. Operating in a pivotal area of the nuclear fuel supply chain for 50 years, Urenco facilitates zero carbon electricity generation for consumers around the world.
With its head office near London, UK, Urenco’s global presence ensures diversity and security of supply for customers through enrichment facilities in Germany, the Netherlands, the UK and the USA. Using centrifuge technology designed and developed by Urenco, and through the expertise of our people, the Urenco Group provides safe, cost effective and reliable services; operating within a framework of high environmental, social and governance standards, complementing international safeguards.
Urenco is committed to continued investment in the responsible management of nuclear materials; innovation activities with clear sustainability benefits, such as nuclear medicine, industrial efficiency and research; and nurturing the next generation of scientists and engineers.
Media enquiries
Sign up to our newsletter by entering your email address below.